Corcept’s ALS drug fails to improve function in Phase 2 study
It’s been a tough few months for Corcept Therapeutics. In October, the company’s lead pipeline candidate missed the primary endpoint in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
